{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:13:37Z","timestamp":1788556417054,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032690","name":"Vyriad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omta.2026.201721","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:06:55Z","timestamp":1773940015000},"page":"201721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-density lipoproteins in human serum competitively inhibit the binding and entry of vesicular stomatitis virus"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6660-0744","authenticated-orcid":false,"given":"Rianna","family":"Vandergaast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal Naik","family":"Nenavath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Schnebeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Narjari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201721_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1279387","article-title":"A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses","volume":"14","author":"Smith","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201721_bib2","doi-asserted-by":"crossref","first-page":"TPS602","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS602","article-title":"Phase 1\/2 trial of vesicular stomatitis virus expressing human interferon-\u03b2 and NIS (VSV-IFN\u03b2-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma","volume":"42","author":"McGarrah","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201721_bib3","doi-asserted-by":"crossref","first-page":"TPS657","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS657","article-title":"Phase 1\/2 trial of vesicular stomatitis virus expressing human interferon-\u03b2 and NIS (VSV-IFN\u03b2-NIS), with pembrolizumab, in patients with neuroendocrine carcinoma","volume":"41","author":"McGarrah","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201721_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00372-23","article-title":"Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2\/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors","volume":"97","author":"Gao","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201721_bib5","article-title":"Optimization of the VSV-G backbone for amino terminal fusion with nanobodies allowing its specific retargeting to HER2 receptors","volume":"33","author":"Duqu\u00e9nois","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omta.2026.201721_bib6","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.1182\/blood-2025-5902","article-title":"Lentiviral vectors engineered for direct In Vivo delivery to resting T cells","volume":"146","author":"Nenavath","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201721_bib7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s41467-018-03432-4","article-title":"Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein","volume":"9","author":"Nikolic","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201721_bib8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1135710","article-title":"Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G","volume":"315","author":"Roche","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.omta.2026.201721_bib9","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1007\/s00018-008-7534-3","article-title":"Structures of vesicular stomatitis virus glycoprotein: Membrane fusion revisited","volume":"65","author":"Roche","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omta.2026.201721_bib10","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1038\/s41467-022-33664-4","article-title":"Atomic model of vesicular stomatitis virus and mechanism of assembly","volume":"13","author":"Zhou","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201721_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.virol.2005.05.006","article-title":"Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells","volume":"338","author":"Sun","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.omta.2026.201721_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/fvl.09.72","article-title":"Internalization and Fusion Mechanism of Vesicular Stomatitis Virus and Related Rhabdoviruses","volume":"5","author":"Sun","year":"2010","journal-title":"Future Virol."},{"key":"10.1016\/j.omta.2026.201721_bib13","first-page":"E28","article-title":"Mechanism of membrane fusion induced by vesicular stomatitis virus G protein","volume":"114","author":"Kim","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201721_bib14","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.4049\/jimmunol.126.4.1562","article-title":"Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum","volume":"126","author":"Beebe","year":"1981","journal-title":"J. Immunol."},{"key":"10.1016\/j.omta.2026.201721_bib15","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4049\/jimmunol.121.4.1549","article-title":"Antibody-Independent Neutralization of Vesicular Stomatitis Virus by Human Complement: I Complement Requirements","volume":"121","author":"Mills","year":"1978","journal-title":"J. Immunol."},{"key":"10.1016\/j.omta.2026.201721_bib16","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1128\/JVI.00074-14","article-title":"Vesiculovirus Neutralization by Natural IgM and Complement","volume":"88","author":"Tesfay","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201721_bib17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/mthe.2000.0116","article-title":"VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum","volume":"2","author":"DePolo","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201721_bib18","doi-asserted-by":"crossref","first-page":"9929","DOI":"10.1128\/JVI.01154-12","article-title":"Virion-Associated Complement Regulator CD55 Is More Potent than CD46 in Mediating Resistance of Mumps Virus and Vesicular Stomatitis Virus to Neutralization","volume":"86","author":"Johnson","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201721_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4049\/jimmunol.118.1.28","article-title":"Effect of selective complement deficiency on the rate of neutralization of enveloped viruses by human sera","volume":"118","author":"Leddy","year":"1977","journal-title":"J. Immunol."},{"key":"10.1016\/j.omta.2026.201721_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0042-6822(82)90125-8","article-title":"The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus I Analysis of neutralizing epitopes with monoclonal antibodies","volume":"121","author":"Lefrancois","year":"1982","journal-title":"Virology"},{"key":"10.1016\/j.omta.2026.201721_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00900-18","article-title":"Characterization of Antibody Interactions with the G Protein of Vesicular Stomatitis Virus Indiana Strain and Other Vesiculovirus G Proteins","volume":"92","author":"Munis","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201721_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34329-3","article-title":"Plasma lipidomic analysis reveals strong similarities between lipid fingerprints in human, hamster and mouse compared to other animal species","volume":"8","author":"Kaabia","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201721_bib23","unstructured":"Russell, S et al. Manuscript in Preparation."},{"key":"10.1016\/j.omta.2026.201721_bib24","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.febslet.2011.03.044","article-title":"Engineered epidermal growth factor mutants with faster binding on-rates correlate with enhanced receptor activation","volume":"585","author":"Lahti","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omta.2026.201721_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1677\/joe.0.1350077","article-title":"Epidermal growth factor concentrations in pig tissues and body fluids measured using a homologous radioimmunoassay","volume":"135","author":"Vaughan","year":"1992","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.omta.2026.201721_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0065-3233(08)60641-5","article-title":"Apolipoprotein B and low-density lipoprotein structure: implications for biosynthesis of triglyceride-rich lipoproteins","volume":"45","author":"Schumaker","year":"1994","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.omta.2026.201721_bib27","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/323738a0","article-title":"Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100","volume":"323","author":"Yang","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201721_bib28","doi-asserted-by":"crossref","first-page":"21682","DOI":"10.1016\/S0021-9258(20)88240-4","article-title":"Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins","volume":"264","author":"Russell","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201721_bib29","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1021\/bi035529y","article-title":"A two-module region of the low-density lipoprotein receptor sufficient for formation of complexes with apolipoprotein E ligands","volume":"43","author":"Fisher","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.omta.2026.201721_bib30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-2275(20)35376-1","article-title":"A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum","volume":"22","author":"Chapman","year":"1981","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.omta.2026.201721_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/humc.2016.061","article-title":"Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFN\u03b2-NIS","volume":"27","author":"Zhang","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omta.2026.201721_bib32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.omtm.2022.12.013","article-title":"Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication","volume":"28","author":"Dambra","year":"2023","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201721_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav7325","article-title":"Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates","volume":"11","author":"Milani","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201721_bib34","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.4049\/jimmunol.158.4.1749","article-title":"T cell priming against vesicular stomatitis virus analyzed in situ: red pulp macrophages, but neither marginal metallophilic nor marginal zone macrophages, are required for priming CD4+ and CD8+ T cells","volume":"158","author":"Ciavarra","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.omta.2026.201721_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/v13030373","article-title":"Functional Dissection of the Dominant Role of CD55 in Protecting Vesicular Stomatitis Virus against Complement-Mediated Neutralization","volume":"13","author":"Asok Kumar","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omta.2026.201721_bib36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.gt.3302399","article-title":"Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation","volume":"12","author":"Schauber-Plewa","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201721_bib37","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1128\/JVI.02832-12","article-title":"PEGylation of Vesicular Stomatitis Virus Extends Virus Persistence in Blood Circulation of Passively Immunized Mice","volume":"87","author":"Tesfay","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201721_bib38","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1128\/JVI.78.2.912-921.2004","article-title":"PEGylation of a Vesicular Stomatitis Virus G Pseudotyped Lentivirus Vector Prevents Inactivation in Serum","volume":"78","author":"Croyle","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201721_bib39","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/mt.2009.282","article-title":"Cocal-pseudotyped Lentiviral Vectors Resist Inactivation by Human Serum and Efficiently Transduce Primate Hematopoietic Repopulating Cells","volume":"18","author":"Trobridge","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201721_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/hum.2020.127","article-title":"In Vivo Gene Therapy for Canine SCID-X1 Using Cocal-Pseudotyped Lentiviral Vector","volume":"32","author":"Rajawat","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201721_bib41","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/blood-2023-187488","article-title":"CD90-Targeted Cocal-Pseudotyped Lentivirus As a Robust Platform for Human HSC Gene Therapy","volume":"142","author":"Thomas","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201721_bib42","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","article-title":"Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation","volume":"33","author":"Andorko","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201721_bib43","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/gt.2013.1","article-title":"Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors","volume":"20","author":"Hwang","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201721_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.13","article-title":"Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis","volume":"2","author":"Tong","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omta.2026.201721_bib45","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/mt.2016.70","article-title":"Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells","volume":"24","author":"Humbert","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201721_bib46","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1128\/JVI.01788-09","article-title":"Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA Targeting","volume":"84","author":"Kelly","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201721_bib47","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1128\/JVI.76.2.895-904.2002","article-title":"Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant Disease","volume":"76","author":"Fernandez","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201721_bib48","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1006\/jmbi.1996.0598","article-title":"Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site","volume":"263","author":"Schier","year":"1996","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.omta.2026.201721_bib49","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nbt0997-871","article-title":"Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo","volume":"15","author":"Zufferey","year":"1997","journal-title":"Nat. Biotechnol."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:29:57Z","timestamp":1788553797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X2600056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3117387X2600056X"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201721","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-density lipoproteins in human serum competitively inhibit the binding and entry of vesicular stomatitis virus","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201721"}}